GENETIC-AF
A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure
- Stage
- klaar
- Medicine
- bucindolol
- Population
- Hartfalen
- Phase
- IIb-IIIa
- First Patient In
- -
- Last Patient In
- 1 July 2017
- Last Patient Last Visit
- 30 December 2017
National Lead
prof. dr. M. Rienstra
Study Director
drs. H.G.R. Dorman
Cardioloog
Board Contact
